Dupixent Hits Endpoints In Adolescents, Filing Expected In Q3

16 May 2018

• By John Davis

Positive top-line Phase III results have been released on the use of Sanofi/Regeneron's Dupixent in adolescents with moderate-to-severe atopic dermatitis, adding to the evidence supporting its use in adults.

A skin condition may arguably have a greater impact on the well-being of adolescents than on adults, underlining the importance of Sanofi and Regeneron Pharmaceuticals Inc. reporting on May 16 positive Phase III results with Dupixent (dupilumab) in the younger age group of patients with inadequately controlled moderate-to-severe atopic dermatitis.

The interleukin4/IL-13 inhibitor, Dupixent, is the first and only biologic to show positive results as monotherapy in adolescents aged 12...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

06 Jun 2025

• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.